The stock soared more than 700% through 2020 and into the first weeks of 2021, and peak vaccine sales reached more than $18 billion for the 2022 full year. But, as demand for coronavirus vaccines ...

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...

Roivant posted a net income of $355.7 million or $0.28 per share, compared to consensus estimates of a loss of $0.34, according to Fiscal.ai data. ・The bottom line was lifted by a $770.2 million gain ...

Moderna stock rose 4% on Monday, extending its 12% rally on Friday. What’s behind the move: The biotech is researching ...

This development renewed investor confidence in Moderna’s mRNA pipeline, even as a cluster of hantavirus cases emerged on a ...

Shares of Moderna ( MRNA) were up nearly 7% in recent trading, following a 12% jump Friday, after Bloomberg reported the ...

Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as well as business outlook for 2026 and beyond. It also outlined some expected ...

Moderna (NASDAQ:MRNA) shares climbed 10% on Thursday as concerns mounted over a hantavirus outbreak connected to a cruise ship.

The FDA refused last week to consider Moderna's application to sell a flu vaccine in 2026-2027. Today, the FDA changed its mind. The FDA had previously rejected Moderna's application, refusing even to ...

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The ...